Kuntai capsules in treatment of premature ovarian failure: A systematic review and meta-analysis

Abstract

ObjectiveTo assess the effectiveness and safety of Kuntai capsules (KTC) in treatment of premature ovarian failure (POF). MethodA systematic review and meta-analysis of randomized controlled trials studied KTC alone or combined with hormone therapy (HT) used for treating POF. PubMed, Cochrane Library, China National Knowledge Infrastructure, China Biology Medicine, Chinese Scientific Journal and Wanfang database were searched until July 2019. The Cochrane risk of bias method was used to assess the quality of the included studies, a meta-analysis was conducted with Review Manager 5.3 software and the level of evidence was rated by using GRAEDpro 3.6 software. ResultsA total of 14 RCTs (1257 participants) were included. Meta-analysis indicated that KTC can significantly improve the total clinical effective rate (P < 0.00001) and the serum hormone levels (P < 0.00001), with no statistically significant report of adverse reactions (P = 0.07) compared with HT. By the subgroup meta-analysis, the results of KTC combined with HT group were similar compared with the original analysis in the serum hormone level (P < 0.00001), and the KTC alone group were better in FSH and LH level (P < 0.00001) but not in E2 level (P = 0.22). Based on the GRADE system for grading, the qualities of the evidence were not high. ConclusionKTC may be effective for POF treatment, and lower risk of side effects. More high-quality articles are needed to provide more reliable sources and data to evaluate the clinical efficacy of KTC in the future.